Form 4 - Statement of changes in beneficial ownership of securities
July 05 2024 - 3:00PM
Edgar (US Regulatory)
SEC Form 4
| FORM 4 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
|
| OMB APPROVAL |
| OMB Number: |
3235-0287 |
| Estimated average burden |
| hours per response: |
0.5 |
|
|
|
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b). |
|
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. |
1. Name and Address of Reporting Person*
| C/O BIOSIG TECHNOLOGIES, INC. |
| 55 GREENS FARMS ROAD |
(Street)
|
2. Issuer Name and Ticker or Trading Symbol
BioSig Technologies, Inc.
[ BSGM ]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
| X |
Director |
|
10% Owner |
|
Officer (give title below) |
|
Other (specify below) |
|
|
|
|
|
3. Date of Earliest Transaction
(Month/Day/Year)
06/07/2024
|
4. If Amendment, Date of Original Filed
(Month/Day/Year)
|
6. Individual or Joint/Group Filing (Check Applicable Line)
| X |
Form filed by One Reporting Person |
|
Form filed by More than One Reporting Person |
|
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |
|---|
| 1. Title of Security (Instr.
3)
|
2. Transaction Date
(Month/Day/Year) |
2A. Deemed Execution Date, if any
(Month/Day/Year) |
3. Transaction Code (Instr.
8)
|
4. Securities Acquired (A) or Disposed Of (D) (Instr.
3, 4 and 5)
|
5.
Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr.
4)
|
7. Nature of Indirect Beneficial Ownership (Instr.
4)
|
| Code |
V |
Amount |
(A) or (D) |
Price |
| Common Stock |
06/07/2024 |
|
A |
|
50,000 |
A |
$0
|
559,501 |
D |
|
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
|
|---|
| 1. Title of Derivative Security (Instr.
3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Transaction Date
(Month/Day/Year) |
3A. Deemed Execution Date, if any
(Month/Day/Year) |
4. Transaction Code (Instr.
8)
|
5.
Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
3, 4 and 5)
|
6. Date Exercisable and Expiration Date
(Month/Day/Year) |
7. Title and Amount of Securities Underlying Derivative Security (Instr.
3 and 4)
|
8. Price of Derivative Security (Instr.
5)
|
9.
Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
4)
|
10. Ownership Form: Direct (D) or Indirect (I) (Instr.
4)
|
11. Nature of Indirect Beneficial Ownership (Instr.
4)
|
| Code |
V |
(A) |
(D) |
Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
| Explanation of Responses: |
|
| Remarks: |
|
|
/s/ Anthony Amato attorney-in-fact |
07/05/2024 |
|
** Signature of Reporting Person |
Date |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. |
| * If the form is filed by more than one reporting person,
see
Instruction
4
(b)(v). |
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure. |
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |
Exhibit
24.1
POWER
OF ATTORNEY
June 21, 2024
KNOW
ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Anthony Amato as his or her true and lawful attorney-in-fact
and agent, with full power of substitution and resubstitution, for, in the name of, and on behalf of the undersigned, place and stead,
in any and all capacities, (i) to execute any and all filings required to be made by the undersigned in the undersigned’s capacity
as an officer or director or both of BioSig Technologies, Inc. pursuant to Section 13 or Section 16 of the Securities Exchange Act of
1934, as amended (the “Exchange Act”) (or any similar rule with respect to foreign exchanges) or any rule or
regulation thereunder (including any amendment, supplement, and/or exhibit thereto), for, in the name of, and on behalf of the undersigned,
(ii) to do and perform any and all acts for, in the name of, and on behalf of the undersigned which said attorney-in-fact determines
may be necessary or appropriate to complete and execute any and all such filings, amendments, supplements, and/or exhibits, and any and
all other document(s) in connection therewith, (iii) to file such filings, amendments, supplements, exhibits, and/or documents with any
governmental office or agency, whether U.S., foreign, state or local government (including, without limitation, the U.S. Securities and
Exchange Commission and state securities administrators or commissions), or any stock exchange or stock quotation system (including,
without limitation, The NASDAQ Capital Market), as may be required under applicable laws or rules and regulations of any stock exchange
or stock quotation system, and (iv) to perform any and all other acts that, in the opinion of said attorney-in-fact and agent, may be
of benefit to, in the best interest of, or legally required by or for the undersigned, granting unto said attorney-in-fact and agent
full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises,
as fully to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorney-in-fact
and agent shall do or cause to be done by virtue hereof. The undersigned hereby acknowledges that the foregoing attorney-in-fact and
agent, in serving in such capacity at the request of the undersigned, is not assuming any of the responsibilities of the undersigned
to comply with Section 16 or Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder.
This
Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file reports under Section 13
or Section 16 of the Exchange Act (or any similar rule with respect to foreign exchanges) or any rule or regulation thereunder (including
any amendment, supplement, and/or exhibit thereto), unless earlier revoked by the undersigned in a signed writing delivered to Anthony
Amato.
IN
WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed and effective as of the date first written above.
| |
/s/
Frederick D. Hrkac |
| |
Frederick
D. Hrkac |
Exhibit
24.1
POWER
OF ATTORNEY
June 21, 2024
KNOW
ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Anthony Amato as his or her true and lawful attorney-in-fact
and agent, with full power of substitution and resubstitution, for, in the name of, and on behalf of the undersigned, place and stead,
in any and all capacities, (i) to execute any and all filings required to be made by the undersigned in the undersigned’s capacity
as an officer or director or both of BioSig Technologies, Inc. pursuant to Section 13 or Section 16 of the Securities Exchange Act of
1934, as amended (the “Exchange Act”) (or any similar rule with respect to foreign exchanges) or any rule or
regulation thereunder (including any amendment, supplement, and/or exhibit thereto), for, in the name of, and on behalf of the undersigned,
(ii) to do and perform any and all acts for, in the name of, and on behalf of the undersigned which said attorney-in-fact determines
may be necessary or appropriate to complete and execute any and all such filings, amendments, supplements, and/or exhibits, and any and
all other document(s) in connection therewith, (iii) to file such filings, amendments, supplements, exhibits, and/or documents with any
governmental office or agency, whether U.S., foreign, state or local government (including, without limitation, the U.S. Securities and
Exchange Commission and state securities administrators or commissions), or any stock exchange or stock quotation system (including,
without limitation, The NASDAQ Capital Market), as may be required under applicable laws or rules and regulations of any stock exchange
or stock quotation system, and (iv) to perform any and all other acts that, in the opinion of said attorney-in-fact and agent, may be
of benefit to, in the best interest of, or legally required by or for the undersigned, granting unto said attorney-in-fact and agent
full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises,
as fully to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorney-in-fact
and agent shall do or cause to be done by virtue hereof. The undersigned hereby acknowledges that the foregoing attorney-in-fact and
agent, in serving in such capacity at the request of the undersigned, is not assuming any of the responsibilities of the undersigned
to comply with Section 16 or Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder.
This
Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file reports under Section 13
or Section 16 of the Exchange Act (or any similar rule with respect to foreign exchanges) or any rule or regulation thereunder (including
any amendment, supplement, and/or exhibit thereto), unless earlier revoked by the undersigned in a signed writing delivered to Anthony
Amato.
IN
WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed and effective as of the date first written above.
| |
/s/
Frederick D. Hrkac |
| |
Frederick
D. Hrkac |
BioSig Technologies (QB) (USOTC:BSGM)
Historical Stock Chart
From Dec 2024 to Jan 2025
BioSig Technologies (QB) (USOTC:BSGM)
Historical Stock Chart
From Jan 2024 to Jan 2025
